The ICOS/ICOSL system may also be modulated by administration of various immunotherapy agents, and the complexity of expression patterns may explain why ICOS has been associated with both better and worse prognosis, depending on the tumor type and assays used. The gene discussed is ICOSLG; the disease is neoplasm.